Short-Term Tumor Cell Lines from Renal Cell Carcinoma for Use as Autologous Tumor Cell Vaccines in the Treatment of Kidney Cancer

2000 ◽  
Vol 15 (2) ◽  
pp. 161-168 ◽  
Author(s):  
Robert O. Dillman ◽  
Linda D. Beutel ◽  
Andrew N. Cornforth ◽  
Shankar K. Nayak
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Renal Cell ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Tumor Cell Lines ◽  
Short Term ◽  
Tumor Cell Vaccines

Treatment of Kidney Cancer with Autologous Tumor Cell Vaccines of Short-Term Cell Lines Derived from Renal Cell Carcinoma

2001 ◽  
Vol 16 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Louis A. VanderMolen ◽  
David H. Garfield ◽  
Cristina De Leon ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Kidney Cancer ◽  
Renal Cell ◽  
Autologous Tumor Cell ◽  
Autologous Tumor ◽  
Short Term ◽  
Tumor Cell Vaccines

Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma

2004 ◽  
Vol 19 (5) ◽  
pp. 570-580 ◽  
Author(s):  
Robert Dillman ◽  
Neil Barth ◽  
Louis VanderMolen ◽  
Khosrow Mahdavi ◽  
Linda Beutel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Renal Cell ◽  
Specific Treatment ◽  
Tumor Cell Line ◽  
Patient Specific ◽  
Autologous Tumor Cell ◽  
Autologous Tumor

scholarly journals LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chunxiu Yang ◽  
Jingjing Pang ◽  
Jian Xu ◽  
He Pan ◽  
Yueying Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Renal Cell ◽  
Bioinformatics Analysis ◽  
Clear Cell ◽  
Tumor Cell Lines ◽  
Cell Renal Cell Carcinoma ◽  
Gene Target

Abstract Background Clear cell renal cell carcinoma (ccRCC), derived from renal tubular epithelial cells, is the most common malignant tumor of the kidney. The study of key genes related to the pathogenesis of ccRCC has become important for gene target therapy. Methods Bioinformatics analysis of The Cancer Genome Atlas (TCGA), the NCBI Gene Expression Omnibus (GEO) database, USUC Xena database, cBioPortal for Cancer Genomics, and MethSurv were performed to examine the aberrant genetic pattern and prognostic significance of leucine-rich repeat kinase 2 (LRRK2) expression and its relationship to clinical parameters. Immunohistochemistry and Western blot were performed to verify LRRK2 expression. The regulation of ccRCC tumor cell lines proliferation by LRRK2 was examined by CCK8 assay. Results Bioinformatics analysis showed that LRRK2 expression was up-regulated and largely correlated with DNA methylation in ccRCC. The up-regulation of LRRK2 was confirmed in ccRCC tissue immunohistochemically and by protein analysis. The level of expression was related to gender, pathological grade, stage, and metastatic status of ccRCC patients. Meanwhile, Kaplan–Meier analysis showed that high expression of LRRK2 correlates to a better prognosis; knockdown of LRRK2 expression attenuated the proliferation ability of ccRCC tumor cell lines; protein–protein interaction network analysis showed that LRRK2 interacts with HIF1A and EGFR. Conclusion We found that LRRK2 may play an important role in the tumorigenesis and progression of ccRCC. Our findings provided a potential predictor and therapeutic target in ccRCC.

Autologous Tumor Cell Line–Derived Vaccine for Patient-Specific Treatment of Advanced Renal Cell Carcinoma

2004 ◽  
Vol 19 (5) ◽  
pp. 570-580 ◽  
Author(s):  
Robert Dillman ◽  
Neil Barth ◽  
Louis VanderMolen ◽  
Khosrow Mahdavi ◽  
Linda Beutel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Renal Cell ◽  
Specific Treatment ◽  
Tumor Cell Line ◽  
Patient Specific ◽  
Autologous Tumor Cell ◽  
Autologous Tumor

Aberrant Expression in Human Epithelial Cancers of the P2X5-Encoded Minor Histocompatibility Antigen LRH-1: Implications for Graft-Versus-Tumor Immunity Against Solid Tumors.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1795-1795
Author(s):  
Harry Dolstra ◽  
Henriette Levenga ◽  
Ingrid Overes ◽  
Johanna C.M. Vos ◽  
Agnes van Horssen-Zoetbrood ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Cell ◽  
Cell Carcinoma ◽  
Cell Lines ◽  
Solid Tumor ◽  
Renal Cell ◽  
Carcinoma Cell ◽  
Tumor Cell Lines ◽  
Renal Cell Carcinoma Cell ◽  
Carcinoma Cell Lines

Abstract Allogeneic stem cell transplantation (SCT) in combination with donor lymphocyte infusion (DLI) is an experimental treatment for patients with metastatic solid tumors. The therapeutic efficacy is attributed to the graft-versus-tumor (GVT) response during which donor-derived T cells eliminate malignant cells via recognition of minor histocompatibility antigens (MiHA). To reduce accompanying GVHD, it is crucial to identify MiHA which are selectively expressed on hematopoietic cells and solid tumor cells. Previously, we identified a hematopoietic cell-restricted MiHA, designated LRH-1, which is presented by HLA-B7 and encoded by the P2X5 purinergic receptor gene (J. Clin. Invest.2005:115:3506–3516). Here, we report that LRH-1, in addition to its hematopoietic cell-restricted expression, is aberrantly expressed on epithelial tumor cell lines. We observed that P2X5 mRNA is significantly expressed in 14 out of 42 (33%) solid tumor cell lines tested by real-time quantitative RT-PCR. We detected P2X5 transcripts in 3 out of 11 renal cell carcinoma cell lines, 2 out of 4 melanoma cell lines, 3 out of 7 colorectal carcinoma cell lines, 4 out of 10 brain tumor cell lines and 2 out of 10 breast cancer cell lines. To determine whether P2X5 mRNA expression in solid tumor cell lines results in susceptibility to lysis by LRH-1-specific CTL, we performed flow cytometry-based cytotoxicity assays using P2X5-expressing tumor cell lines. Based on LRH-1 genotyping analysis, we selected six solid tumor cell lines for the cytotoxicity studies. Remarkably, LRH-1-specific CTL efficiently lysed and inhibited the growth of DAOY brain tumor cells up to 3 days of co-culture. The renal cell carcinoma cell lines SKRC-33 and SKRC-18 and the melanoma cell line BLM were also susceptible to LRH-1 CTL-mediated lysis, although less effectively. However, pre-incubation of these tumor cell lines with IFNγ and TNFα significantly increased the susceptibility to LRH-1-specific CTL and resulted in complete target cell lysis. Furthermore, these cytokine-stimulated cell lines induced higher levels of CTL degranulation as determined by CD107a staining. No cytotoxicity was observed against LRH-1-negative FM3 melanoma and SKRC-24 renal cell carcinoma cell lines. These findings illustrate that the GVT reactivity observed in solid tumors after allogeneic SCT may be selectively enhanced by LRH-1-specific immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document